Humana Stock Falls as Medicare Advantage Ratings Decline
Shares of Humana took a hit as the health insurer announced a drop in the quality ratings of its Medicare Advantage plan, impacting future bonus payments. The company revealed that only 25% of its customers are currently enrolled in plans rated four stars or higher for 2025, a significant drop from 94% this year. Furthermore, the rating for a major national insurance plan that covers 45% of Humana’s enrollment dipped to 3.5 points.
According to Leerink Partners analyst Whit Mayo, this ratings decline could result in a $1.9 billion revenue loss in 2026 unless Humana implements measures to address the issue. Medicare Advantage plans, which are privately operated versions of the federal Medicare program primarily for individuals aged 65 and above, are currently facing challenges such as increased claims costs and more hospital visits.
Despite the setback, Humana remains optimistic about its performance and is in discussions with federal authorities to address the reduction in ratings. The company is committed to enhancing its operations to regain its star rating. While the ratings drop is not expected to impact Humana’s results or outlook for the current year and the next, the company is exploring various options to offset the anticipated revenue decline in 2026.
As a prominent provider of Medicare Advantage coverage, Humana’s stock witnessed a 13% drop in Wednesday afternoon trading, contributing to a 47% decrease since the beginning of the year. The company is closely monitoring the situation and working towards improving its ratings and financial outlook moving forward.
The annual enrollment period for 2025 Medicare Advantage coverage commences on October 15, with individuals having until December 7 to finalise their coverage choices for the following year. Analysts and industry experts are closely observing Humana’s response to the ratings downgrade and its impact on the broader healthcare landscape.